Evotec Establishes Research Collaboration With Harvard University and the Howard Hughes Medical Institute in Diabetes Research

Thursday, 10. March 2011 07:56
Evotec AG /
Evotec Establishes Research Collaboration With Harvard University and the Howard
Hughes Medical Institute in Diabetes Research
Processed and transmitted by Thomson Reuters.
The issuer is solely responsible for the content of this announcement.

* Collaboration Established to Drive Innovation and Develop New Diabetes
Therapies Targeting Beta Cell Regeneration


Hamburg, Germany ; 10 February 2011: Evotec AG (TecDax: EVT) today announced the
establishment of a research collaboration with Harvard University and the Howard
Hughes Medical Institute (HHMI) aimed at discovering and developing new
 treatments in the field of  diabetes.

The initial goal of the collaboration is to pursue a comprehensive and
systematic approach towards the identification and development of physiological
mechanisms and targets that regulate beta cell replication. Harvard, HHMI, and
Evotec bring together extensive expertise and know-how in beta cell biology and
diabetes along with an unparalleled set of tools to exploit beta cell related
mechanisms and targets. This unique collaboration will be fueled by substantial
scientific contributions from Harvard and HHMI as well as Evotec's firm
commitment to deliver on their common goal to develop orally available small
molecule therapies that trigger or support beta cell replication.

Therapies that trigger/support beta cell replication are expected to enhance or
even restore the body's ability to produce sufficient insulin to maintain
optimal glycemic control and thereby reduce and prevent the development of
diabetic complications. Leveraging key insights about beta cell replication and
forming co-development alliances with pharmaceutical companies at the
appropriate point in the development chain are the core strategic drivers of the
collaboration.

"We are very proud to have entered into this collaboration with Harvard and
HHMI. We are convinced that it will lead to the development of a pipeline of
exciting drug candidates in diabetes," said Dr. Cord Dohrmann, CSO of Evotec.
 "Existing therapies have proven largely ineffective against the progression of
most degenerative diseases including diabetes. We are enthusiastic about
exploring new mechanisms that have the potential to restore beta cell function
and produce first-in-class therapeutics for the treatment of diabetes in
collaboration with Harvard and HHMI."

Dr. Doug Melton, Thomas Dudley Cabot Professor at Harvard University, and an
investigator at the Howard Hughes Medical Institute, will be the principal
investigator for Harvard and HHMI.

"We're very pleased to enter into this collaboration with Evotec, which joins
together leaders in academic research and industry to progress groundbreaking
research more rapidly from the lab to the clinic", said Isaac T. Kohlberg,
Harvard's Chief Technology Development Officer and head of its Office of
Technology Development. "It exemplifies Harvard's commitment to creatively
partner with industry in ways that will advance the boundaries of translational
science and fulfill our mandate to serve the public interest"

Further details and commercial terms of the cooperation are not disclosed.


ABOUT DOUG MELTON
Doug Melton is the Thomas Dudley Cabot Professor of Natural Sciences at Harvard
University and an Investigator of the Howard Hughes Medical Institute.  His
laboratory focuses on the development of the pancreas and the use of stem cell
approaches to find new treatments for diabetes.


ABOUT EVOTEC AG
Evotec is a leader in the discovery and development of novel small molecule
drugs with operational sites in Europe and Asia. The Company has built
substantial drug discovery expertise and an industrialized platform that can
drive new innovative small molecule compounds into the clinic. In addition,
Evotec has built a deep internal knowledge base in the treatment of diseases
related to neuroscience, pain, oncology, inflammation and metabolic diseases.
Leveraging these skills and expertise the Company intends to develop best-in-
class differentiated therapeutics and deliver superior science-driven discovery
alliances with pharmaceutical and biotechnology companies. Evotec has long-term
discovery alliances with partners including Boehringer Ingelheim, MedImmune,
CHDI, Genentech, Novartis, Ono Pharmaceutical and Roche. Evotec has product
candidates in clinical development and a series of preclinical compounds and
development partnerships, including for example a strategic alliance with Roche
for the EVT 100 compound family, subtype selective NMDA receptor antagonists for
use in treatment-resistant depression and an alliance in the field of diabetes
with Andromeda (Teva). For additional information please go towww.evotec.com.

ABOUT HARVARD UNIVERSITY'S OFFICE OF TECHNOLOGY DEVELOPMENT
The Harvard Office of Technology Development (OTD) is responsible for all
activities pertaining to the evaluation, patenting and licensing of new
inventions and discoveries made at Harvard University and Harvard Medical
School. OTD also serves to further the development of Harvard technologies
through the establishment of sponsored research collaborations with industry.
OTD's mission is to promote the public good by fostering innovation and
translating new inventions made at Harvard into useful products available and
beneficial to society.


Contact: Dr Werner Lanthaler, Chief Executive Officer, Evotec AG, Tel.:
+49.(0)40.56081-242, werner.lanthaler@evotec.com


FORWARD-LOOKING STATEMENTS - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. Such forward-looking statements include, but are not limited to,
statements about our expected 2010 financial results and financial growth in
2011, our anticipated financing needs, our ability to deliver on our liquidity
guidance, our belief that we are on course to sustainable profitability latest
in 2012, our expectations and assumptions concerning regulatory, clinical and
business strategies, the progress of our clinical development programmes and
timing of the commencement and results of our clinical trials, strategic
collaborations and management's plans, objectives and strategies. These
statements are neither promises nor guarantees, but are subject to a variety of
risks and uncertainties, many of which are beyond our control, and which could
cause actual results to differ materially from those contemplated in these
forward-looking statements. In particular, the risks and uncertainties include,
among other things: risks that product candidates may fail in the clinic or may
not be successfully marketed or manufactured; the risk that we will not achieve
the anticipated benefits of our collaborations, partnerships and acquisitions in
the timeframes expected, or at all; risks relating to our ability to advance the
development of product candidates currently in the pipeline or in clinical
trials; our inability to further identify, develop and achieve commercial
success for new products and technologies; the risk that competing products may
be more successful; our inability to interest potential partners in our
technologies and products; our inability to achieve commercial success for our
products and technologies; our inability to protect our intellectual property
and the cost of enforcing or defending our intellectual property rights; our
failure to comply with regulations relating to our products and product
candidates, including FDA requirements; the risk that the FDA may interpret the
results of our studies differently than we have; the risk that clinical trials
may not result in marketable products; the risk that we may be unable to
successfully secure regulatory approval of and market our drug candidates; and
risks of new, changing and competitive technologies and regulations in the U.S.
and internationally.
The list of risks above is not exhaustive. Our most recent Annual Report on Form
20-F, filed with the Securities and Exchange Commission, and other documents
filed with, or furnished to the Securities and Exchange Commission, contain
additional factors that could impact our businesses and financial performance.
We expressly disclaim any obligation or undertaking to release publicly any
updates or revisions to any such statements to reflect any change in our
expectations or any change in events, conditions or circumstances on which any
such statement is based.


--- End of Message ---

Evotec AG
Schnackenburgallee 114 Hamburg Germany

WKN: 566480;ISIN: DE0005664809;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;


Pdf of PressRelease:
http://hugin.info/131215/R/1495914/431596.pdf




This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Evotec AG via Thomson Reuters ONE

[HUG#1495914]
Related Links: Evotec SE
Author:
Hugin
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.